- Home
- TRS vs VRDN Comparison
TRS vs VRDN Comparison
Compare TRS & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRS | VRDN |
|---|---|---|
| Founded | 1986 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2004 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TRS | VRDN |
|---|---|---|
| Price | $36.13 | $14.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $41.50 | $35.46 |
| AVG Volume (30 Days) | 378.9K | ★ 3.4M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | ★ 400.00 | N/A |
| EPS | ★ 2.95 | N/A |
| Revenue | ★ $645,720,000.00 | $5,706,000.00 |
| Revenue This Year | $5.42 | $13.73 |
| Revenue Next Year | $4.27 | $279.00 |
| P/E Ratio | $12.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.81 | $11.76 |
| 52 Week High | $42.00 | $34.29 |
Technical Indicators
Market Signals| Indicator | TRS | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 43.81 | 24.61 |
| Support Level | $35.41 | $13.59 |
| Resistance Level | $37.20 | $19.42 |
| Average True Range (ATR) | 1.05 | 1.00 |
| MACD | -0.18 | 0.22 |
| Stochastic Oscillator | 17.20 | 15.67 |
Price Performance
Historical ComparisonAbout TRS TriMas Corporation
TriMas Corp designs, develops and manufactures a diverse set of products for the consumer products, and industrial markets . The company operates through two segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners. The packaging segment generates majority of its revenue.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.